Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2022) 84 PS1-02-18 | DOI: 10.1530/endoabs.84.PS1-02-18

1Berlin Institute of Health, Core Unit Stem Cells, Berlin, Germany; 2Charité – Universitätsmedizin Berlin, Center for Stroke Research Berlin, Department of Neurology With Experimental Neurology, Germany; 3Charité Universitätsmedizin Berlin, 3) Institute of Experimental Pediatric Endocrinology, Charité – Universitätsmedizin, Institut für Experimentelle Pädiatrische Endokrinologie, Berlin, Germany; 4Berlin Institute of Health, Bih Core Unit Bioinformatics, Charité – Universitätsmedizin Berlin, Core Unit Bioinformatics, Berlin, Germany; 5Charité-Universitätsmedizin Berlin, Institute of Experimental Endocrinology, Charité – Universitätsmedizin Berlin, Institut für Experimentelle Endokrinologie, Berlin, Germany; 6Institut für Experimentelle Endokrinologie, Charité - Universitätsmedizin Berlin, Charité-Universitätsmedizin Berlin, Institut für Experimentelle Endokrinologie, Institute for Experimental Endocrinology, Berlin, Germany; 7Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Experimental Endocrinology, Charité – Universitätsmedizin Berlin, Institut für Experimentelle Endokrinologie, Berlin, Germany; 8Charité - Universitätsmedizin Berlin, Department of Neurology With Experimental Neurology, Center for Stroke Research Berlin, Charité – Universitätsmedizin Berlin, Klinik F. Neurologie, Berlin, Germany; 9Berlin Institute of Health, Bih Stem Cell Core, Berlin Institute of Heath at Charité – Universitätsmedizin Berlin, Core Unit Stem Cells, Berlin, Germany

Thyroid hormones (TH) play a fundamental role in brain development. Changes on TH availability during pregnancy and early childhood can lead to neurological disorders. Accordingly, concerns are mounting that exposure to environmental compounds capable of interfering with TH action can disrupt neuronal development. Current approaches to categorize chemicals as thyroid hormone system disrupting chemicals (THSDC) are mainly based on determination of changes in circulating TH concentrations in vivo. Since such tests are not adequate to capture alterations at cellular and molecular levels during human brain development, there is an urgent need to establish and validate human in vitro models for THSDC assessment. Human cerebral organoids (hCOs) derived from induced pluripotent stem cell (hiPSC) present a promising model system as hCOs recapitulate tissue complexity and critical developmental processes while providing an infinite source of material. We used single cell hCO transcriptome data to extract lists of TH-responsive genes to be used as molecular markers of TH action in RT-qPCR assays. Since hCOs show dynamic changes in cell composition during their development, these lists included broad response genes as well as cell type-specific markers. We analyzed expression patterns of marker genes following acute 48 h treatment of hCOs at different stages with T3 (3-300 nM). We further characterized expression profiles following co-exposure of hCOs to T3 and the MCT8 inhibitor silychristin (SC) or the pan-deiodinase inhibitor iopanoic acid (IA). In addition, we established a sensitive LC-MS/MS method to determine basal TH concentrations in media and the TH metabolite pattern (rT3, 3,3´-T2; 3,5-T2; 3-T1; T0) following TH treatment and co-exposure experiments. RT-qPCR assays of whole hCOs showed significant gene expression changes in a TH concentration-dependent manner for most of the selected marker genes. SC co-treatment attenuated the T3-induced expression response for a subset of genes (i.e., CADM2, DBP and DIO3) in acute T3 treatment schemes. IA co-treatment enhanced T3-induced expression levels in longer-term T3 treatment schemes. Cell type composition (progenitors, neurons) had a clear influence on T3-induced expression responses as evident from comparison of T3 effects in early and late stage hCOs. hCOs effectively metabolize T3 to 3,3´T2. Notably, metabolic degradation of T3 was reduced upon co-treatment with either SC or IA. Thus, these reference compounds affected both molecular markers and local T3 metabolism. Our study demonstrates the utility of hCOs as a promising platform for THSDC assessment, identifies critical aspects (validation, endpoints, reference compounds) and highlights pitfalls for the assay validation process.

Volume 84

44th Annual Meeting of the European Thyroid Association (ETA) 2022

Brussels, Belgium
10 Sep 2022 - 13 Sep 2022

European Thyroid Association 

Browse other volumes

Article tools

My recent searches

No recent searches.